Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00796328
Other study ID # IWK-4462-2008
Secondary ID
Status Terminated
Phase Phase 4
First received November 19, 2008
Last updated March 22, 2018
Start date November 2008
Est. completion date July 2009

Study information

Verified date March 2018
Source IWK Health Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to determine the ED90 for an infusion of phenylephrine to prevent spinal induced low blood pressure in parturients presenting for an elective cesarean delivery. The up-down methodology (UDM) is commonly used study method to determine the dose of a drug that causes the desired effect in over 90% of the subjects to whom it given. For example: the investigators want to know what is the best dose of phenylephrine (from a range of commonly used doses) to prevent a drop in blood pressure during cesarean delivery ninety times out of one hundred when it is given at that dose. The ED90 is the effective dose at which 90% of subjects will have a "positive" response to a phenylephrine infusion, i.e. no drop in blood pressure. The investigators hypothesize that the ED90 will be between 40 - 60 mcg/min.

The primary outcome measure is the ED90 for phenylephrine infusions that prevents a drop in blood pressure in women undergoing cesarean delivery.


Recruitment information / eligibility

Status Terminated
Enrollment 45
Est. completion date July 2009
Est. primary completion date February 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Non-emergent cesarean delivery with planned spinal anesthesia (i.e. elective planned cesarean delivery for malposition, patient choice, cervical pelvic disproportion, previous cesarean delivery and other diagnosis that require a predetermined cesarean delivery)

2. American Society of Anesthesia physical status class I & II (ASA I - Healthy, ASA II - mild and controlled systemic disease, eg. controlled essential hypertension)

3. Age = 18 years (Standard within the obstetrical literature)

4. Term gestational age

5. English-speaking

Exclusion Criteria:

1. Morbid Obesity (Body Mass Index = 45 kg/m2) (Morbidly obese parturients require a dose of local anesthetic less than the standardized dose in this study, typically have an exaggerated response to vasopressors, and the blood pressure cuff occasionally needs to be replaced by an intra-arterial catheter due to limitations in size)

2. Height < 5'0" (Women < 5'0" are likely to require a dose of local anesthetic less than the standardized dose in this study)

3. Laboring women

4. Urgent or emergency cesarean delivery

5. Hypertensive disease of pregnancy

6. Severe maternal cardiac disease

7. Subjects on monoamine oxidase inhibitors (MAOI's) or tricyclic antidepressants

8. Fetal anomalies or intrauterine fetal death

9. Failed spinal anesthesia

10. Subject enrollment in another study involving a study medication within 30 days of CD

11. Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection

Study Design


Related Conditions & MeSH terms

  • Hypotension
  • Spinal Induced Hypotension in Cesarean Delivery

Intervention

Drug:
Phenylephrine infusion
Up-down, biased coin design

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
IWK Health Centre

Outcome

Type Measure Description Time frame Safety issue
Primary Effective Dose of Phenylephrine at Which 90% of Subjects Have no Spinal Induced Hypotension The effective dose at which 90% of subjects will have a "positive" response to a phenylephrine infusion, i.e. no spinal induced hypotension. We hypothesize that the ED90 will be between 40 - 60 mcg/min. Spinal administration until delivery